HTG MOLECULAR DIAGNOSTICS, INC (HTGM) [Rocket]

In millions, except per share items	Mar-31-23	Mar-05-23	Jun-30-22	Mar-31-22	Mar-05-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	8-K	10-Q	10-Q	8-K	10-K	10-Q	10-Q
Total revenues			8.1	8.7		8.9	8.6	7.9
Revenue growth			2.6%	11.6%		4.2%	-20.0%	-45.3%
Cost of goods sold			4.2	4.2		4.1	3.8	3.8
Gross profit			3.9	4.5		4.8	4.8	4.1
Gross margin			47.9%	51.9%		54.0%	55.9%	52.3%
Selling, general and administrative [+]			21.5	20.6		17.8	17.7	18.2
Sales and marketing			17.0	16.0			13.3	13.8
General and administrative						4.6
Research and development						4.8	4.1
Other operating expenses			0.9	-2.5				-3.0
EBITDA [+]			-21.3	-16.3		-14.1	-13.1	-13.9
EBITDA growth			53.5%	-7.2%		-22.5%	-29.3%	-22.8%
EBITDA margin			-263.7%	-188.4%		-158.7%	-151.8%	-176.3%
Depreciation and amortization			0.7	0.7		0.7	0.9	1.0
EBIT [+]			-22.0	-17.0		-14.9	-14.0	-14.9
EBIT growth			47.7%	-9.4%		-24.1%	-29.8%	-22.9%
EBIT margin			-272.4%	-196.6%		-166.8%	-162.0%	-189.2%
Interest expense, net [+]			0.5	0.5		0.8	0.8	0.8
Interest expense			0.5	0.5		0.8	0.8	0.8
Interest income			0.0	0.0		0.0	0.0	0.1
Other income (expense), net			0.4	-1.2				-1.5
Pre-tax income			-22.1	-18.8		-17.1	-16.2	-17.1
Income taxes			0.0	0.0		0.0	0.0	0.0
Net income			-22.1	-18.8		-17.1	-16.2	-17.2
Net margin			-273.3%	-217.1%		-192.5%	-188.6%	-218.1%

Basic EPS [+]			($3.39)	($3.46)		($2.53)	($2.62)	($3.10)
Growth			9.5%	-15.2%		-45.0%	-49.9%	62.4%
Diluted EPS [+]			($3.39)	($3.46)		($2.53)	($2.62)	($3.10)
Growth			9.5%	-15.2%		-45.0%	-49.9%	62.4%

Shares outstanding (basic) [+]			6.5	5.4		6.8	6.2	5.5
Growth			17.4%	9.3%		49.4%	54.5%	-47.9%
Shares outstanding (diluted) [+]			6.5	5.4		6.8	6.2	5.5
Growth			17.4%	9.3%		49.4%	54.5%	-47.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.